Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448

Cohen, Paul A.; Powell, Aime; Böhm, Steffen; Gilks, C Blake; Stewart, Colin J.R.; Meniawy, Tarek; Bulsara, Max; Avril, Stefanie; Brockbank, Eleanor; Bosse, Tjalling; Focchi, Gustavo Rubino de Azevedo; Ganesan, Raji; Glasspool, Rosalind; Howitt, Brooke E.; Kim, Hyunsoo; Lee, Jung‐Yun; Le, Nhu D.; Lockley, Michelle; Manchanda, Ranjit; Mandalia, Trupti; McCluggage, W. Glenn; McNeish, Iain A.; Midha, Divya; Srinivasan, Radhika; Tan, Yun Yi; Griend, Rachael van der; Yunokawa, Mayu; Zannoni, Gian Franco; Singh, Naveena

doi:10.1016/j.ygyno.2021.01.032

Cited by 11 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CA125 level as a measure for clinical outcome can be debated. CA125 is elevated in, on average, 80% of EOC patients at time of diagnosis [22]. In our study, one patient did not have elevated CA125 at diagnosis.…”

Section: Discussioncontrasting

confidence: 42%

“…This points out the difficulty of determining an appropriate measure for clinical outcome. Therefore, in an expansion of this study, different variables to measure the response to chemotherapy will be taken into account, including CA125 level, outcome of CT-scan using RECIST-criteria [24,25], outcome of the debulking surgery, and the histopathologic chemotherapy response score [22]. These variables, together with platinum sensitivity, PFS, and OS will further substantiate the conclusion for clinical outcome.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites

Ouden¹,

Zaman

Dylus

et al. 2020

Oncotarget

View full text Add to dashboard Cite

Background: In epithelial ovarian cancer (EOC), 15-20% of the tumors do not respond to first-line chemotherapy (paclitaxel with platinum-based therapy), and in recurrences this number increases. Our aim is to determine the feasibility of cell proliferation assays of tumor cells isolated from malignant ascites to predict in vitro chemotherapy sensitivity, and to correlate these results with clinical outcome.Materials and Methods: Ascites was collected from twenty women with advanced EOC. Cell samples were enriched for tumor cells and EOC origin was confirmed by intracellular staining of CK7, surface staining of CA125 and EpCAM, and HE4 gene expression. In vitro sensitivity to chemotherapy was determined in cell proliferation assays using intracellular ATP content as an indirect measure of cell number. In vitro drug response was quantified by calculation of the drug concentration at which cell growth was inhibited with 50%. Clinical outcome was determined using posttreatment CA125 level.Results: Cell samples of twenty patients were collected, of which three samples that failed to proliferate were excluded in the analysis (15%). Three other samples were excluded, because clinical outcome could not be determined correctly. In twelve of the fourteen remaining cases (86%) in vitro drug sensitivity and clinical outcome corresponded, while in two samples (14%) there was no correspondence.Conclusions: Our study demonstrates the feasibility of drug sensitivity tests using tumor cells isolated from ascites of advanced EOC patients. Larger observational studies are required to confirm the correlation between the in vitro sensitivity and clinical outcome.

show abstract

Section: Discussioncontrasting

confidence: 42%

Section: Discussionmentioning

confidence: 96%

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites

Ouden¹,

Zaman

Dylus

et al. 2020

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Since its definition by Bohm and colleagues in 2015, CRS has been validated in multiple cohorts as a reproducible histopathologic scoring system that provides valuable prognostic information for women with tubo-ovarian cancer treated with NACT/IDS (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). First, our study corroborates these findings in a large dataset.…”

Section: Discussionsupporting

confidence: 81%

“…Notably, while most studies have focused on high-grade serous carcinoma, our cohort includes other types of high-grade cancers, with 11% representing other high-grade ovarian tumors. Despite including additional tumor types, our CRS score distribution remained comparable to other studies and was most similar to a meta-analysis that examined 877 cases of high-grade serous carcinoma across multiple centers internationally (11). This may suggest that CRS warrants further investigation to determine whether it may apply more broadly to other high-grade tubo-ovarian tumors.…”

Section: Discussionsupporting

confidence: 77%

“…In women with stage IIIC/IV high-grade serous carcinoma treated with NACT/IDS, CRS predicted progression-free survival (PFS) (8,9). Subsequent studies demonstrated reproducibility and provided external validation of CRS in additional cohorts of women with advanced stage epithelial tubo-ovarian cancer (10)(11)(12)(13)(14)(15)(16)(17)(18). The CRS system has been incorporated into histopathologic evaluation guidelines published by the International Collaboration on Cancer Reporting and the College of American Pathologists (19,20).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Impact of Ki-67 Labeling Index on Prognostic Significance of the Chemotherapy Response Score in Women With Tubo-ovarian Cancer Treated With Neoadjuvant Chemotherapy

Heayn

Skvarca

Zhu

et al. 2020

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

The chemotherapy response score (CRS) proposed by Bohm and colleagues in 2015 has been validated as a reproducible method for determining histopathologic response of tubo-ovarian carcinoma to neoadjuvant chemotherapy and stratifies tumor response into 3 groups: CRS1 is defined as minimal/no response, CRS2 as moderate response, and CRS3 as marked response. Although described as a 3-tiered system, it essentially works as a 2-tiered system (CRS1/CRS2 vs. CRS3) for assessing prognosis. Here, we analyzed the prognostic value of CRS in a large cohort of tubo-ovarian carcinomas at a tertiary care center and evaluated the potential for Ki-67 labeling index on post-neoadjuvant chemotherapy samples to provide additional prognostic information. We included 170 patients with tubo-ovarian carcinoma treated with neoadjuvant chemotherapy followed by interval debulking surgery. We determined CRS for each case by reviewing slides from the interval debulking surgery resection specimen and calculated progression-free survival and overall survival. For each case with residual disease (CRS1 and CRS2, n = 123, 72%), we also performed Ki-67 antibody staining and determined both average and highest Ki-67 labeling index. Consistent with prior studies, patients in our cohort with CRS1 and CRS2 showed significantly shorter progression-free survival and overall survival compared with CRS3. Further, in the subset of cases with CRS1 and CRS2, Ki-67 labeling index was predictive of OS at multiple cutoff points. An average Ki-67 labeling index of 20% (log rank test P-value: 0.0004) or a highest Ki-67 labeling index of 50% (log rank test P-value: 0.0002) could provide a practically useful cutoff. Multivariable cox proportional hazard model showed worse overall survival with both, average Ki-67 > 20% (hazard ratios: 2.02, P-value: 0.00422, confidence interval: 1.25-3.28) and highest Ki-67 > 50% (hazard ratios: 1.88, P-value: 0.0205, confidence interval: 1.1-3.2). We propose adding Ki-67 labeling index to CRS to provide additional prognostic separation between patients with CRS1 and CRS2.

show abstract

Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones

Denisenko,

de Kock,

Tan

et al. 2024

Nat Commun

View full text Add to dashboard Cite

High-grade serous ovarian carcinoma (HGSOC) is genetically unstable and characterised by the presence of subclones with distinct genotypes. Intratumoural heterogeneity is linked to recurrence, chemotherapy resistance, and poor prognosis. Here, we use spatial transcriptomics to identify HGSOC subclones and study their association with infiltrating cell populations. Visium spatial transcriptomics reveals multiple tumour subclones with different copy number alterations present within individual tumour sections. These subclones differentially express various ligands and receptors and are predicted to differentially associate with different stromal and immune cell populations. In one sample, CosMx single molecule imaging reveals subclones differentially associating with immune cell populations, fibroblasts, and endothelial cells. Cell-to-cell communication analysis identifies subclone-specific signalling to stromal and immune cells and multiple subclone-specific autocrine loops. Our study highlights the high degree of subclonal heterogeneity in HGSOC and suggests that subclone-specific ligand and receptor expression patterns likely modulate how HGSOC cells interact with their local microenvironment.

show abstract

Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448

Abstract: Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448

Cited by 11 publications

References 0 publications

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites

Impact of Ki-67 Labeling Index on Prognostic Significance of the Chemotherapy Response Score in Women With Tubo-ovarian Cancer Treated With Neoadjuvant Chemotherapy

Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones

Contact Info

Product

Resources

About